In this arm of the study, those participants who actually achieved and continued on the 4.8 mg dose weight reduction reached 18.7% at week 46 (Le Roux et al, 2023)
It is the first drug in its class to act as both a GLP-1 and a GIP (glucose-dependent insulinotropic polypeptide) receptor agonist
A healthcare provider will determine the right dosage for you
Always ensure your supplement specifies the "L" form
While these recent studies have sparked enthusiasm, Adam Bisaga, MD, professor of clinical psychiatry at Columbia University Vagelos College of Physicians and Surgeons, told Healio that the therapeutic use of these agents for SUDs is not yet robust enough to justify widespread promotion. In fact, there is an inherent danger in overstating potential benefits with low risks, setting unrealistic expectations, and allowing commercial interests to overshadow solid addiction science, he said